Seeking Alpha

ACHN
Achillion Pharmaceuticals, Inc.

5/27/2012, 2:42 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ACHN Market Currents more »
  • May 21 Achillion (ACHN +10.4%), possibly because of the release of positive results from a Phase Ib trial of ACH-2684 for the Treatment of Hepatitis C. Last week, the FDA fast-tracked ACH-3102, also for Hepatitis C. (PR)
    Comment!
    [On the Move, Healthcare]
ACHN in Focus more »
ACHN Latest Transcript more »
Currently, there are no transcripts for ACHN.
ACHN Cramer more »
Currently, there are no Cramer articles on ACHN.
ACHN Instablog posts more »
  • Barchart Morning Call 3/2
    Fri, Mar 2 • Jim Van Meerten • Comment!
  • Trader's Almanac: September 30, 2011
    Fri, Sep 30, 2011 • Edgar Ambartsoumian • Comment!
  • Achillion Pharmaceuticals Inc. (ACHN) Begins Dosing for Hepatitis C Treatment, Prepares for Clinical Milestones
    Mon, Jul 11, 2011 • QualityStocks • Comment!
  • Wednesday, June 22, 2011
    Thu, Jun 23, 2011 • btdstocksblog • Comment!
  • Achillion Pharmaceuticals Inc. (ACHN) Begins First-in-human Dosing for Hepatitis C Treatment
    Wed, May 25, 2011 • QualityStocks • Comment!
Write a post on ACHN
ACHN StockTalks
ACHN vs. ETF Alternatives
Company Description
Currently, there's no company description for ACHN.
Sector: Healthcare
Industry: Biotechnology
Country: United States